Italian science is noticed in the world, and among the protagonists of the annual congress of theAmerican Society of Clinical Oncology (ASCO) – The most prestigious international appointment dedicated to oncology – among the 17 Italian researchers also the name of a young Messina researcher, Paola Zagamioncologist of the European Institute of Oncology (IEO) in Milan.
For the first time in the history of the conference, two doctors from the same center, the renowned IEO of Milan, were selected for the coveted Oral Session Breastdedicated to breast cancer. Together with Giuseppe Curiglianodirector of development new drugs for innovative therapies, to represent Italy there was also Paola Zagami, 34 years old, originally from Messinawho received the prestigious ASCO Merit Award for the excellence and innovation of his scientific work. In total there are 17 researchers from our country who received the prestigious recognition.
Dr. Zagami presented the results of an international study that marks a turning point in the treatment of breast cancer in young women carriers carriers of mutation BRCCA. The analysis involved over 1,800 patients from 109 Centers distributed in 33 countriesmaking it the wider ever conducted on this specific type of oncological population.
The focus of the research was the effect of the suppression of the ovarian function -Through analogues of the LHRH or prophylactic ovariactomy-in women with hormone-sensitive breast cancer. The results are clear: ovarian suppression improves significantly Free disease survival, The interval free from recurrence And global survivalshowing that the intervention plays a decisive role not only in the prevention of ovarian cancer, but also in the reduction of the recurrence of the breast cancer.
“This recognition to SCO represents not only a personal goal, but also an important signal for Italian research and for our commitment to improve patients’ lives“, Said Dr. Zagami, who began her academic career among the classrooms of the University of Messina, before continuing the training in oncology in some of the main European research centers.